A phase II study of irinotecan as single agent in the third-line treatment of unresectable or metastatic gastric cancer.

被引：2
|
作者：
Zhang, Zhe
Chen, Zhiyu
Zhu, Xiaodong
Zhang, Xiaowei
Zhao, Xiaoying
Zhang, Wen
Qiu, Lixin
Huang, Mingzhu
Wang, Chenchen
Guo, Weijian
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e16084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16084
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line treatment in patients with metastatic gastric cancer
    Yu, Nuoya
    Huang, Sha
    Zhang, Zhe
    Huang, Mingzhu
    Wang, Yusheng
    Zhang, Wen
    Zhang, Xiaowei
    Zhu, Xiaodong
    Sheng, Xuedan
    Yu, Kaiyue
    Chen, Zhiyu
    Guo, Weijian
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [2] Efficacy of Irinotecan as Third-line Chemotherapy for Unresectable or Recurrent Gastric Cancer
    Fukuchi, Minoru
    Kuwabara, Kohki
    Ishiguro, Toru
    Kumagai, Youichi
    Ishibashi, Keiichiro
    Mochiki, Erito
    Ishida, Hideyuki
    IN VIVO, 2020, 34 (02): : 903 - 908
  • [3] Irinotecan combined with Panitumumab or cetuximab as third-line treatment for metastatic colorectal cancer.
    Braghiroli, Maria Ignez
    Batistuzzo Vicentini, Maria Fernanda
    da Fonseca, Leonardo Gomes
    Souza, Karla Teixeira
    Bonadio, Renata Colombo
    Melro Braghiroli, Oddone Freitas
    Machado Mathias, Maria Cecilia
    Talans, Aley
    Zambrano Mendoza, Maria Elizabeth
    Martins, Juliana Goes
    Sabagga, Jorge
    Motta Venchiarutti Moniz, Camila Venchiarutti
    Hoff, Paulo Marcelo
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E15551 - E15551
  • [4] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
    Makiyama, Akitaka
    Arimizu, Kohei
    Hirano, Gen
    Makiyama, Chinatsu
    Matsushita, Yuzo
    Shirakawa, Tsuyoshi
    Ohmura, Hirofumi
    Komoda, Masato
    Uchino, Keita
    Inadomi, Kyoko
    Arita, Shuji
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Shinohara, Yudai
    Kuwayama, Miyuki
    Kajitani, Tatsuhiro
    Oda, Hisanobu
    Esaki, Taito
    Akashi, Koichi
    Baba, Eishi
    GASTRIC CANCER, 2018, 21 (03) : 464 - 472
  • [5] Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer
    Akitaka Makiyama
    Kohei Arimizu
    Gen Hirano
    Chinatsu Makiyama
    Yuzo Matsushita
    Tsuyoshi Shirakawa
    Hirofumi Ohmura
    Masato Komoda
    Keita Uchino
    Kyoko Inadomi
    Shuji Arita
    Hiroshi Ariyama
    Hitoshi Kusaba
    Yudai Shinohara
    Miyuki Kuwayama
    Tatsuhiro Kajitani
    Hisanobu Oda
    Taito Esaki
    Koichi Akashi
    Eishi Baba
    Gastric Cancer, 2018, 21 : 464 - 472
  • [6] A retrospective analysis of third-line treatment in advanced gastric cancer.
    Ishizuka, Yasunobu
    Terazawa, Tetsuji
    Yukami, Hiroki
    Yamaguchi, Toshifumi
    Kuwakado, Shin
    Kii, Takayuki
    Goto, Masahiro
    Higuchi, Kazuhide
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
    Takeshi Kawakami
    Nozomu Machida
    Hirofumi Yasui
    Masahiro Kawahira
    Sadayuki Kawai
    Yosuke Kito
    Yukio Yoshida
    Satoshi Hamauchi
    Takahiro Tsushima
    Akiko Todaka
    Tomoya Yokota
    Kentaro Yamazaki
    Akira Fukutomi
    Yusuke Onozawa
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 809 - 814
  • [8] Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer
    Kawakami, Takeshi
    Machida, Nozomu
    Yasui, Hirofumi
    Kawahira, Masahiro
    Kawai, Sadayuki
    Kito, Yosuke
    Yoshida, Yukio
    Hamauchi, Satoshi
    Tsushima, Takahiro
    Todaka, Akiko
    Yokota, Tomoya
    Yamazaki, Kentaro
    Fukutomi, Akira
    Onozawa, Yusuke
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (04) : 809 - 814
  • [9] Chemothery (pacitaxol or irinotecan), plus apatinib and sintilimab as second-/third-line treatment for advanced gastric cancer.
    Deng, Ting
    Zhang, Le
    Duan, Jingjing
    Li, Hongli
    Ge, Shaohua
    Bai, Ming
    Ning, Tao
    Yang, Yuchong
    Ji, Zhi
    Liu, Rui
    Wang, Xia
    Zhang, Haiyang
    Ba, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer
    Brodowicz, T
    Kostler, WJ
    Möslinger, R
    Tomek, S
    Vaclavik, I
    Herscovici, V
    Wiltschke, C
    Steger, GG
    Wein, W
    Seifert, M
    Kubista, E
    Zielinski, CC
    BREAST, 2000, 9 (06): : 338 - 342
12345